Global The Second Generation Ultrasound Contrast Agent Market Growth 2025-2031

The global The Second Generation Ultrasound Contrast Agent market size is predicted to grow from US$ 195 million in 2025 to US$ 486 million in 2031; it is expected to grow at a CAGR of 16.5% from 2025 to 2031.

The second generation ultrasound contrast agent is a kind of microbubble contrast agent coated with high density inert gas (such as perfluoropropane, sulfur hexafluoride, etc.), the microbubble size is usually 2-5 microns, and the outer film is composed of phospholipid or human blood albumin and other materials, which is soft and stable. This contrast agent can reach the left heart and peripheral blood tube through the pulmonary circulation, and realize the development of a variety of organs and tissues. It has a long stable time and good vibration and echo characteristics, which helps to generate strong harmonic signals, so as to obtain real-time harmonic images with low noise, and improve the resolution, sensitivity and specificity of ultrasonic diagnosis.

United States market for The Second Generation Ultrasound Contrast Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for The Second Generation Ultrasound Contrast Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for The Second Generation Ultrasound Contrast Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key The Second Generation Ultrasound Contrast Agent players cover Bracco, GE Healthcare, Lantheus Medical Imaging, ImaRx Therapeutics, Microvascular Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “The Second Generation Ultrasound Contrast Agent Industry Forecast” looks at past sales and reviews total world The Second Generation Ultrasound Contrast Agent sales in 2024, providing a comprehensive analysis by region and market sector of projected The Second Generation Ultrasound Contrast Agent sales for 2025 through 2031. With The Second Generation Ultrasound Contrast Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world The Second Generation Ultrasound Contrast Agent industry.

This Insight Report provides a comprehensive analysis of the global The Second Generation Ultrasound Contrast Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on The Second Generation Ultrasound Contrast Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global The Second Generation Ultrasound Contrast Agent market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for The Second Generation Ultrasound Contrast Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global The Second Generation Ultrasound Contrast Agent.

This report presents a comprehensive overview, market shares, and growth opportunities of The Second Generation Ultrasound Contrast Agent market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Perfluorocarbons
Sulfur Hexafluoride
Others

Segmentation by Application:
Cardiovascular Imaging
Liver Imaging
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bracco
GE Healthcare
Lantheus Medical Imaging
ImaRx Therapeutics
Microvascular Therapeutics
Solstice Pharmaceuticals
Daiichi Sankyo Company
Siemens Healthineers AG
NanoPET Pharma
Beijing Qihui Biopharmaceuticals
Beijing Ferrymed Medical Technology
SUNΛ Med-Engineering
Xiamen LP Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global The Second Generation Ultrasound Contrast Agent market?

What factors are driving The Second Generation Ultrasound Contrast Agent market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do The Second Generation Ultrasound Contrast Agent market opportunities vary by end market size?

How does The Second Generation Ultrasound Contrast Agent break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.